NCT00312364

Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 322 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a clinical research study of an experimental topical drug for the treatment of chronic, neuropathic, diabetic foot ulcers. Patients participating in the study may receive an active drug (MRE0094), inactive drug (placebo), or a gel used to treat diabetic foot ulcers currently available for sale in the United States. What treatment a patient will receive is determined by chance (like drawing a number from a hat). All patients will receive additional care for diabetic foot ulcers during the study. Participation in the study can be up to 4½ months.

Conditions

• Foot Ulcer, Diabetic
• Diabetes Complications

Interventions

Type	Name	Description
DRUG	MRE0094

Timeline

• Start date: 2005-12-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2006-04-10
• Last updated: 2012-06-01

Locations

63 sites across 1 country: United States